HTHendrick T. Tevaearai

Hendrick T. Tevaearai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hendrick T. Tevaearai has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 363 Apoptosis Occurs in Late Stages of Unloading Related Ventricular Remodeling

    by H.L. Brinks, T.P. Carrel, W.J. Koch, H.T. Tevaearai, M.-N. Giraud

  • Open Access

    Donor heart contractile dysfunction following prolonged ex vivo preservation can be prevented by gene-mediated β-adrenergic signaling modulation

    by Hendrik T. Tevaearai, G. Brant Walton, Andrea D. Eckhart, Janelle R. Keys, Walter J. Koch

    Objectives: Reperfusion after myocardial ischemia goes together with alteration of the β-adrenergic (βAR) signaling. Especially the level and catalyt


    • 1 March 2002
      • Vol. 122  (3) , 149-53

    [Gene therapy and benefits in modulating of system beta-adrenergic in cardiac insufficiency].

    by Hendrik T Tevaearai, G Brant Walton, Walter J Koch

    Understanding the basic molecular mechanisms that lead to heart failure may allow to define new targets for myocardial gene therapy. In this way, the alterations of the beta-adrenergic signaling that are typically observed in cardiac insufficiency, may be positively modulated by gene manipulation. Both the level and activity of the beta-adrenergic receptor kinase (beta ARK1), a regulatory enzyme that phosphorylates agonist occupied beta-adrenoreceptors, are elevated and account for desensitization of cardiomyocytes to catecholamines. We recently demonstrated that expressing beta ARKct, a peptide which inhibits beta ARK1, allows normalization of contractile function in several animal models of heart failure. This approach may represent a valuable alternative for the treatment of heart failure. The current review summarizes recent studies performed using beta ARKct as a transgene to restore normal beta-adrenergic signaling and improve myocardial function.

    • 1 December 2001
      • Vol. 49  (6) , 389-94

    Gene-mediated inhibition of the b-adrenergic receptor kinase: a new therapeutic strategy for heart failure.

    by H T Tevaearai, A D Eckhart, W J Koch

    Molecular changes that take place during the evolution of heart failure (HF), especially the well characterized beta-adrenergic receptor (betaAR) signaling abnormalities, represent attractive targets for myocardial gene therapy. The beta-adrenergic receptor kinase (betaARK1 or GRK2) is a cytosolic enzyme that phosphorylates only agonist-occupied betaARs as well as other G protein-coupled receptors (GPCRs), leading to desensitization and functional uncoupling. betaARK1 levels and activity are elevated in the failing heart and therefore, it has recently been evaluated as a potential target for novel HF treatment. This review summarizes recent results obtained in transgenic mouse models as well as in animals where a betaARK1 inhibitor peptide (betaARKct) was delivered via the coronary arteries by exogenous gene transfer. These results strongly suggest that betaARK1 inhibition may represent a significant improvement in HF therapy.


    • 1 August 2001
      • Vol. 42  (4) , 443-9

    Tricuspid valve involvement in combined mitral and aortic valve surgery.

    by X M Mueller, H T Tevaearai, F Stumpe, A P Fischer, M Hurni, P Ruchat, L K Von Segesser

    Combined mitral and aortic valve disease requiring surgery may involve the tricuspid valve as well. Our treatment policy is conservative especially for tricuspid regurgitation which is operated on when severe only. A retrospective study was performed at a tertiary and secondary referral center for cardiovascular disease. Over a 15-year period, 65 consecutive patients underwent aortic and mitral surgery with concomitant tricuspid regurgitation and/or stenosis. Fifty-five/65 (85%) patients were in NYHA class III-IV. Fifty-eight/65 (89%) patients had tricuspid regurgitation secondary to right chamber dilatation and 7/65 (11%) had tricuspid stenosis and/or regurgitation because of previous endocarditis. Twenty-two/65 (34%) tricuspid valves were operated on: 18/22 (82%) de Vega annuloplasty, 2/22 (9%) commissurotomies and 2/22 (9%) prosthetic valves. Mortality and complications were recorded during a mean follow-up of 5.3 yrs (range, 6 months-15.3 yrs). Event-free survivals were determined using the Kaplan-Meier method. Hospital mortality was 6.2% (4/65) and the complication rate was 18.5% (12/65). The freedom from late valve related mortality and morbidity at 5, 10 and 15 years was 86+/-5.5%, 81.9+/-6.8%, and 81.9+/-6.8% respectively. One valve related complication was due to the tricuspid valve. At last follow-up, 87% (47/54) of the survivors were in NYHA class I-II. With a conservative policy of tricuspid valve intervention, functional results of this patient population are good and long-term valve related morbidity and mortality are mainly related to the mitral and aortic valve procedures.


  • Intrachannel versus Interchannel Application of Angiogenic Factors in Transmyocardial Laser Revascularization

    by X M Mueller, H T Tevaearai, C Y Genton, P Chaubert, von Segesser

    Background and Objective: Theoretically myocardial angiogenesis of laser injury can be further enhanced by the addition of angiogenic growth factors. The influence of the way of administration of these factors on vascular growth around the channels is still unclear. Materials and Methods: 18 pigs (mean weight 72 +/- 5.2 kg) were randomized to either triads of transmyocardial laser revascularization (TMLR) channels (group 1, n = 6) or isolated channels (group 2, n = 6), or a control group (n = 6). The animals had injections of bovine bone derived growth factor mixture either in the center of the triads in group 1 or within the channels themselves in group 2. Animals were sacrificed one month later for histological analysis. Results: The vascular densities of myocardial areas within the triads of group 1 and around the channels in group 2 were significantly larger than in the control group: 15.2 +/- 3.7/mm2 and 14.2 +/- 3.5/mm2 respectively vs 5.3 +/- 1.6/mm2(p < 0.001 for both differences). Differences of densities between group 1 and 2 were not statistically significant (p = 0.6).


  • Performance of a New Implantable Cardiac Assist Centrifugal Pump

    by Hendrik T. Tevaearai, Xavier M. Mueller, David Jegger, Monique Augsburger, Marco Burki, Ludwig K. Von Segesser


    • 1 December 2000
      • Vol. 99  (6) , 535-40

    Improved neoangiogenesis in transmyocardial laser revascularization combined with angiogenic adjunct in a pig model.

    by X M Mueller, H T Tevaearai, C Y Genton, P Chaubert, L K Von Segesser

    Recent research has revealed neoangiogenesis as a basic phenomenon in transmyocardial laser revascularization (TMLR). Theoretically, myocardial neoangiogenesis could be further enhanced by the addition of angiogenic growth factors. Triads of TMLR channels were created in the lateral wall of the left ventricles of 12 pigs (mean body weight 73+/-5 kg), using a holmium:yttrium-aluminium garnet (YAG) laser. The animals were allocated randomly either to receive an injection of 100 microg of a bovine bone-derived growth factor mixture within the triads (n=6), or to a control group (n=6). Animals were killed 1 month later. Capillary and arteriolar densities were determined by computed morphometric analysis of histological sections of the triads. The capillary density of myocardial areas within the triads was significantly greater in the group receiving the bovine bone-derived growth factor mixture than in the control group (14.3+/-3.5/mm(2) and 5.7+/-1.4/mm(2) respectively; P<0.001). The difference was also significant when considering arteriolar density (0.7+/-0.4/mm(2) and 0.2+/-0.1/mm(2) respectively; P<0.001). For comparison, capillary and arteriolar densities of the TMLR channel scars were 48.7+/-9.7 and 1.9+/-0. 5/mm(2) respectively in the angiogenic group, and 46.3+/-13.7 and 2. 3+/-1.3/mm(2) respectively in the control group (no significant differences). These results demonstrate that the addition of angiogenic factors to TMLR stimulates neoangiogenesis significantly in the areas adjacent to the channels, but not within the channel scars. The latter are themselves strongly vascularized. Hence this combined approach, potentiating the effect of TMLR by establishing vascular connections between the neovessels of the channel scars, has the potential for improved clinical outcome.

  • Impact of Hollow-Fiber Membrane Surface Area on Oxygenator Performance: Dideco D903 Avant Versus a Prototype with Larger Surface Area

    by Xavier M. Mueller, Hendrick T. Tevaearai, David Jegger, Yves Boone, Monique Augstburger, Ludwig K. von Segesser

    This study compares the gas transfer capacity, the blood trauma, and the blood path resistance of the hollow-fiber membrane oxygenator Dideco D 903 with a surface area of 1.7 m2 (oxygenator 1.7) versus a prototype built on the same principles but with a surface area of 2 m2 (oxygenator 2).Six calves (mean body weight: 68.2 ± 3.2 kg) were connected to cardiopulmonary bypass (CPB) by jugular venous and carotid arterial cannulation, with a mean flow rate of 4l/min for 6 h. They were randomly assigned to oxygenator 1.7 (N = 3) or 2 (N = 3). After 7 days, the animals were sacrificed. A standard battery of blood samples was taken before the bypass, throughout the bypass, and 24 h, 48 h, and 7 days after the bypass.The oxygenator 2 group showed significantly better total oxygen and carbon dioxide transfer values throughout the perfusion (p < .001 for both comparison). Hemolytic parameters (lactate dehydrogenase and free plasma hemoglobin) exhibited a slight but significant increase after 5 h of bypass in the oxygenator 1.7 group. The pressure drop through the oxygenator was low in both groups (range, 43–74 mmHg).With this type of hollow-fiber membrane oxygenator, an increased surface of gas exchange from 1.7m2 to 2 m2 improves gas transfer, with a limited impact on blood trauma and no increase of blood path resistance.


    • 1 July 2000
      • Vol. 120  (7) , 569-72

    [Closure of an atrial septal defect by a mini-thoracotomy with the help of extra-corporal circulation].

    by J Berthod, H T Tevaearai, X M Mueller, E Mabillard, L K Von Segesser, F Stumpe

    "Minimal invasive" surgical closure of an atrial septal defect (ASD) is performed under femoro-femoral CPB, the superior vena cava being (IVC) drained by a supplementary cannula placed directly through the thoracic opening. We present a new technique where both vena cavae are drained by a single 2 stage femoral cannula. The cannula is introduced through the femoral vein and its distal holes are directed into the superior vena cava (SVC) while the proximal holes are maintained into the IVC. A centrifugal pump is placed on the venous line between the cannula and the venous reservoir in order to improve the venous return. Both IVC and SVC are clamped around the cannula to isolate the right atrium before opening it and repairing the ASD. We recently operated on a 60 years old man using this technique. Passive venous drainage was 2.6 l/min whereas the perfusion theoretical flow was 5.4 l/min. But adding the centrifugal pump increased the flow to 5.4 l/min which ensured an optimal perfusion flow. CPB time was 38 minutes and operative time was 140 minutes. There were no complications and the patient returned home at day 5 following the operation. Using a single venous cannula for drainage of both vena cavae simplifies the technique and therefore contributes to the development of "minimally invasive" cardiac surgery.